Alessandro Broccoli

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers

Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies

Interim [¹⁸F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Radioimmunotherapy of human tumours

Current trends in the treatment of primary mediastinal large B-cell lymphoma – an overview

HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts

Matching chelators to radiometals for radiopharmaceuticals

Tumour-associated macrophages as treatment targets in oncology

Development of therapeutic antibodies for the treatment of diseases

Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Role of Functional Imaging in the Management of Lymphoma

Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Natural product and natural product derived drugs in clinical trials

CutaneousT‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management

A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome

Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome

Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial

CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Rituximab Combined With MACOP-B or VACOP-B and Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study

The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B‐cell lymphoma: experience on 74 patients

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study

Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.

The prognostic value of biologic markers in classical hodgkin lymphoma (CHL) patients.

Role of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma